Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc has recently improved its financial position through equity financings and option exercises, leading to increased financing income of $284K for the quarter and $611K year-to-date, reflecting enhanced interest earnings from marketable securities. The company is on track for a full launch of its LIBERTY Endovascular Robotic System in the U.S. by Q2 2026, with significant enhancements to its commercial and production capabilities, including an expanded team and a partnership with a third-party logistics provider. Expectations of accelerating growth from the upcoming product launches in various regions further solidify Microbot’s competitive position, which could justify a premium valuation for the stock.

Bears say

Microbot Medical faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include delays in the commercialization of its LIBERTY system, difficulties in expanding applications to neuro and cardio cases, and setbacks in securing international regulatory approvals, all of which could hinder revenue growth. Additionally, the company is grappling with a lack of near-term profitability, reimbursement headwinds, and potential market penetration issues, which could further impact its financial performance.

Microbot Medical (MBOT) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.